The Effect of Colchicine on HDL functions in patients with Acute Coronary Syndrome

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000039188

Enrollment

Unknown

Registered

2020-10-21

Start date

2020-11-01

Completion date

Unknown

Last updated

2021-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute coronary syndrome

Interventions

Standard ACS treatment group:standard ACS treatment and placebo

Low-dose colchicine group:standard ACS treatment and 0.5mg qd colchicine

High-dose colchicine group:standard ACS treatment and 1.0mg qd colchicine

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 80 years; 2. Specific diagnosis of ACS, including the ST-elevated or non ST-elevated AMI from ECG, high-risk unstable angina (classic cheset pain, electrocardiogram changes), positive marker of myocardial injury (CK-MB or TnT), or the evidence supporting from coronary angiogram; 3. The hsCRP level was more than 2mg/l; 4. Before deciding to participate, patients or their relatives sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Allergy sufferer, particularly allergic to colchicine, or under the treatment of colchicine. 2. Patients suffered from inflammatory bowel disease, chronic diarrhea or neuromuscular diseases. 3. Patients suffered from severe wasting disease, such as malignant tumor, tuberculosis. 4. Sever hypohepatia (ALT 3 times higher than upper normal limit), renal insufficiency (CKD 3 or wrose), uncontrolled auto-immune diseases, or taking long-term courses of glucocorticoids. 5. Sever heart failure (EF < 35%), Type II myocardial infarction. 6. Severe trauma or major surgery. 7. At the acute stage of infectious diseases. 8. Hyperthyreosis or hypothyroidism. 9. During pregnancy or lactation; reproductive age women who do not take any precautions.

Design outcomes

Primary

Measure	Time frame
myocardial enzyme;NT-BNPpro;liver function;renal function;coronary angiogram;Heart Doppler ultrasound;triglyceride;high-density lipoprotein;low-density lipoprotein;total cholesterol;free fatty acid;apolipoprotein AI;apolipoprotein B;HDL oxidative inflammation index;HDL-sphingosine-1 phosphate;HDL-PLA2 activity;HDL-apolipoprotein A-1;HDL-apolipoprotein C-3;HDL-SSA;HDL - mediated cholesterol efflux;hsCRP;IL-6;IL-18;MPO;	—

Measure

Time frame

myocardial enzyme;NT-BNPpro;liver function;renal function;coronary angiogram;Heart Doppler ultrasound;triglyceride;high-density lipoprotein;low-density lipoprotein;total cholesterol;free fatty acid;apolipoprotein AI;apolipoprotein B;HDL oxidative inflammation index;HDL-sphingosine-1 phosphate;HDL-PLA2 activity;HDL-apolipoprotein A-1;HDL-apolipoprotein C-3;HDL-SSA;HDL - mediated cholesterol efflux;hsCRP;IL-6;IL-18;MPO;

—

Secondary

Measure	Time frame
Blood routine;	—

Countries

China

Contacts

Public ContactDaoquan Peng

Second Xiangya Hospital

pengdq@csu.edu.cn+86 13974822567

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026